

Ein cyf/Our ref: NICE TAs to Dec 2013 [4]
Gofynnwch am/Please ask for: Sue Beach
Rhif Ffôn /Telephone: 01554 783084
Ffacs/Facsimile:
E-bost/E-mail: sue.beach@wales.nhs.uk

Dr Carol Llewellyn-Jones
Glangwili General Hospital
Dolgwili Road, Carmarthen,
Carmarthenshire, SA31 2AF
Tel: 01267 235151

Dr Carol Llewellyn-Jones
Ysbyty Cyffredinol Glangwili
Heol Dolgwili, Caerfyrddin
Sir Gaerfyrddin, SA31 2AF
Rhif Ffôn: 01267 235151

7th February 2014

BY EMAIL

Page 1 of 2

**TO: All prescribers
County lead pharmacists
Assistant Director of Nursing (Practice)
Hywel Dda Health Board global email**

Dear Colleague

The appraisals listed below have been published by the National Institute for Health & Care Excellence (NICE). They have been assessed for local implementation and their place in therapy established as described.

Please ensure that your teams are fully aware of this information.

In accordance with the provisions of Welsh Health Circulars WHC 2003 (109) and 2005 (22), see WHC (2003) 109 (<http://howis.wales.nhs.uk/doclib/whc-2003-109-e.pdf>) and WHC (2005) 22 (http://howis.wales.nhs.uk/doclib/WHC_2005_022.pdf), the drugs have been added to the Health Board's formulary, <http://hywelddahb.inform.wales.nhs.uk/>, and are available for prescribing in accordance with the guidance.

Please ensure that the appropriate audit form is completed for all patient initiations on these technologies in the next 12 months. You will find the audit forms on the Clinical Systems (NICE / TA AWMSG appraisal audits) pages of the Health Board's Intranet:
<http://howis.wales.nhs.uk/sitesplus/862/page/43199>

Pharmacy has been notified of the guidance and you should be aware that a prescription that falls outside the recommendations of the guidance will be discussed with the prescriber. Failure to complete the audit form may result in a delay in dispensing.

NICE TA294, July 2013, Macular degeneration (wet age-related) - aflibercept (1st line):
<http://guidance.nice.org.uk/TA294>

Approved and added to the Formulary. Specialist ophthalmology use and Hospital only.

NICE TA283, May 2013, Macular oedema (retinal vein occlusion) – ranibizumab:
<http://guidance.nice.org.uk/TA283>

Approved and added to the Formulary. Specialist ophthalmology use and Hospital only.

Pencadlys Bwrdd Iechyd Hywel Dda
Llys Myrddin, Lôn Winch, Hwlfordd,
Sir Benfro, SA61 1SB
Rhif Ffôn: (01437) 771220
Rhif Ffacs: (01437) 771222

Hywel Dda Health Board Headquarters
Merlins Court, Winch Lane, Haverfordwest,
Pembrokeshire, SA61 1SB
Tel Nr: (01437) 771220
Fax Nr: (01437) 771222

Cadeirydd / Chairman
Mr Chris Martin
Prif Weithredwr / Chief Executive
Yr Athro/Professor Trevor Purt

Bwrdd Iechyd Hywel Dda yw enw gweithredol Bwrdd Iechyd Lleol Hywel Dda
Hywel Dda Health Board is the operational name of Hywel Dda Local Health Board

Mae Bwrdd Iechyd Hywel Dda yn amgylchedd di-fwg Hywel Dda Health Board operates a smoke free environment

NICE TA274, February 2013, Macular oedema (diabetic) – ranibizumab:

<http://guidance.nice.org.uk/TA274>

Approved and added to the Formulary. Specialist ophthalmology use and Hospital only.

If you have any questions relating to the guidance or this process, please contact Sue Beach, Lead Clinical Development Pharmacist, on 01554 783084 or 0777 21 77 655 or email sue.beach@wales.nhs.uk.

Dr Carol Llewellyn-Jones
Consultant Physician
Chairman, Medicines Management Group
AMD Carmarthenshire

A signed copy is kept on file